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Patent Harmonization Can Enhance the Global Competitiveness
of Canada and the United States
William H. Duffey*
I. INTRODUCTION AND BACKGROUND
t
I goes without saying that Canada and the United States would both be

highly receptive to any initiative which could enhance their respective
positions in the aggressive arena of global competition. While it cannot
be touted as a panacea or salvation for this phenomenon of global competitiveness, the notion of harmonizing patent laws among major trading
partners is regarded by many experts as a tangible and timely initiative
which deserves strong support.
Many legal experts scoff at the idea of achieving a new international
treaty which would introduce identical patent laws throughout the
world. Many regard this concept as unrealistic and fruitless. Some critics argue that, even if an international harmonization treaty were to
emerge from the World Intellectual Property Organization ("WIPO")
within the next year or two, few countries would ratify the treaty.
However, serious tripartite (trilateral) discussions are proceeding
among representatives of the Japanese Patent Office ("JPO"), the European Patent Office ("EPO"), and the U.S. Patent and Trademark Office
("USPTO"). While it is too early to make predictions on the success or
the outcome of these trilateral talks, the main topics on the agenda
should attract the attention of all major industrialized countries which
purport to offer hospitality to intellectual property rights.
This Paper highlights the major items of substantive patent law
which have occupied the agenda in the trilateral consultations. Focus on
these key issues may serve to alert other industrialized nations to the
kinds of patent law principles which could be susceptible to ultimate
adoption in a harmonization agreement.
Much patience and understanding is required by the trilateral participants as they sit with each other and seriously move forward in an
effort to ultimately forge a meaningful harmonization package. The
agreement must transcend the diverse legal, economic, cultural, political
and social traditions represented by each of the constituencies.
Ironically, despite the differences in national traditions and backgrounds represented by the trilateral participants, there is not an enormous gulf between the three states in many important areas of patent
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practice. Therefore, the notion of achieving trilateral harmonization in
certain fundamental areas of patent practice is more feasible than many
of the critics would suggest. For example, it is clearly feasible to seek
uniformity in the duration of patents, i.e., the official patent term. Following are the current practices of the respective trilateral patent offices
on the matter of patent duration, together with a model patent term proposed for harmonization purposes.
DURATION OF PATENTS

U.S. System
Term: 17 years
without regard to
filing date.

European System
Term: 20 years from
filing date.

Japanese System
Term: 15 years from
publication, not to
exceed 20 years from
filing.
ProposedHarmonizationModel: Minimum term 20 years from the earliest domestic filing date.
With respect to Canadian practice, the patent term has traditionally
been the same as the current U.S. practice. However, under Sections 4548 of Canadian Bill C-22 which received Royal Assent on November 19,
1987, the new patent term will be 20 years from the date of filing the
application in Canada. If the Amended Patent Act comes into force as
expected, Canada will already be in line with the proposed harmonization model. It should also be noted that several other provisions of the
Canadian Bill C-22 are in line with proposals in the trilateral harmonization model. An example is the issuance of patents to the first-to-file inventor rather than the first-to-invent inventor. Canada's adoption of the
first-to-file priority system would leave the United States and the Philippines the only countries still using a first-to-invent priority system.
II.

BROAD SCOPE OF PATENTABLE SUBJECT MATTER

Here is a substantive issue of patent law which can have significant
impact on global competition. Perhaps the best illustration of the importance of the broad scope of patentable subject matter is whether or not a
given country will grant product protection for pharmaceutical compounds. There is an enormous amount of research and development
costs required to discover a new drug and to bring it through clinical
trials, government approval and market introduction. The latest quantitative estimates by the U.S. Pharmaceutical Manufacturers Association
("PMA") report that the introduction of a single new drug typically requires a period of ten years coupled with an expenditure of approximately $110 million. The need for patent protection to shelter marketing
profits in order to simply break-even in such a high stakes game must be
obvious.
Yet many countries of the world still have not seen fit to provide
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adequate protection within their patent laws for pharmaceutical compounds. Indeed, those same countries which resist granting pharmaceutical patent protection on the grounds that such protection would be
deleterious to the national health interests of that country's inhabitants
are often the same countries that blatantly misappropriate, pirate or
counterfeit the pharmaceutical inventions of others. Thus, the pharmaceutical field represents one science where global reform is long overdue
for the protection of the intellectual property rights of inventors.
The following comparison illustrates the current disparity now existing among states with respect to scope of patentable subject matter.
U.S. System
European System
Japanese System
Broad scope of
Somewhat limited
Somewhat limited
patentable subject
scope of patentable
scope of patentable
matter.
subject matter.
subject matter.
Proposed Harmonization Model Broad scope of patentable subject matter.
An objective of the proposed model is to make patent rights available for
all technologies. An example for needed reform is found in the biotechnology brought about in the past decade through molecular biology and
genetic engineering. These new and powerful techniques of gene splicing
and cloning have led to the creation of genetically engineered plants and
seeds. Unfortunately, article 53(b) of the European Patent Convention
prohibits the granting of patents for "plant and animal varieties." In
contrast, the USPTO, in the decision of Ex parte Hibberd,1 held that
genetically transformed plants are susceptible to utility patent protection
under 35 U.S.C. section 101.
Thus, a European agrichemical firm can obtain a utility patent for a
genetically transformed plant or seed in the United States under the Hibberd doctrine, thereby obtaining exclusivity for the claimed subject matter. That same European firm is unable to obtain patent protection in the
EPO for the same invention. The situation is even more severe for the
U.S. agricultural firm which is barred from utility patent protection in
Europe under EPO article 53(b) and, in addition, must compete against
its European competitor who can take advantage of U.S. patent shelters.
Thus, the case for patent harmonization is an urgent matter affecting
global competition.
III.

FIRST-TO-FILE PRIORITY SYSTEM

Mention was made earlier of the fact that the United States still
adheres to the first-to-invent priority system. The EPO and JPO have
long adhered to the first-to-file system. In a good faith effort to advance
trilateral harmonization the USPTO has indicated a willingness to
change from the first-to-invent to the first-to-file practice but only as
part of a balanced package to improve international standards of patent
I Ex Parte Hibberd,

227 U.S.P.Q. 443 (1985).

CANADA-UNITED STATES LAW JOURNAL

Vol. 14:271 1988

protection. Once again, this underscores the fact that trilateral harmonization is not merely a fantasy but rather a reachable goal which is achievable if the delegates remain open-minded and cooperative.

IV.

EIGHTEEN MONTH PUBLICATION

One feature expected in any model harmonization treaty, whether a
trilateral model or a WIPO model, is a provision for publication of patent applications eighteen months from the effective priority filing date.
The EPO and JPO already follow this practice and the trend is clearly in
this direction. The Canadian Bill C-22 section 10 provides that patent
applications and documents will be open to public inspection after the
expiry of eighteen months from the effective filing date. At present, Canadian patent applications and related documents are kept secret until
the Canadian patent is issued.
V.

OTHER PROPOSED HARMONIZATION ITEMS

The trilateral harmonization negotiators are faced with several other
prominent issues. These include a one year grace period prior to the
convention priority date. This permits inventors to publicly disclose
their inventions before filing a patent application without losing patent
rights. An objective test for nonobviousness is being discussed, along
with a plan which would permit any number of independent and dependent patent claims, separately enforceable. The states are also considering adoption of: a peripheral claiming practice (i.e., the claim recites the
metes and bounds of-the invention), a broad claim interpretation, and a
post-grant re-examination of patents.
Another caveat which deserves mention is the posture of the EPO
delegates at the trilateral talks. The EPO delegates have been very careful to reiterate that, in the area of substantive patent law, they have no
mandate. That is, the member states of the European Patent Convention
have not given the EPO any mandate to negotiate in this area. Furthermore, the EPO points out that the European Patent Convention itself is
nearly impossible to change. All of this portends lengthy negotiations.
VI.

CONCLUSION

While many skeptics in the patent community scoff at attempts by
WIPO and others to genuinely seek greater harmony among national
patent laws, there is an unmistakable current of optimism and palpable
progress emerging from the trilateral talks. While the trilateral talks are
only a modest beginning, it is incumbent on patent lawyers in the North
American patent community to support the momentum which our governments have initiated toward meaningful reform and harmony within
the global context of patent laws.
Canada is to be commended for its most recent initiative with Canadian Bill C-22 which seems to anticipate the ultimate results being sought
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not only in the trilateral context, but also in the global context of harmonization. If the trilateral talks bear fruit, there will most certainly be a
salubrious effect on the global competitiveness of Canada, the United
States and other industrialized nations.

